Plenty of disgruntled shareholders at the moment. It has been very frustrating
for all of us, me included. Hard to believe we are sitting at 12 cents. There has also
been a few posters here nocking management, specifically Paul Hopper and Leslie Chong.
I do believe some of the criticism is warranted but not all. Yes, I agree IMU has not done
a great job at marketing the company. In my opinion they should source that out to a
professional marketing company and let Leslie concentrate on all other things company wise.
I think Leslie Chong is doing a magnificent job overall as CEO and Managing Director.
For those late commers to IMU just remember this, if it wasn't for our CEO Leslie Chong
the CF33 platform would not be with IMU, it would have gone elsewhere.
You see when Paul Hopper originally tried to get that IP, he was planning a separate company
for it. More money in his pocket I guess is what he was thinking, and good luck to him, for he
knows this stock market game inside out, being an ex-broker himself. But thanks to Leslie, she
insisted that she wanted the CF33 platform for IMU, and Paul finally gave in. Thank goodness
for that, because in my opinion CF33 platform will be the big maker of this company.
Just to show how IMU have not done a great job of marketing the company I will give you a
personal experience. I have a close family member going through cancer treatment as we
speak. I take them into the hospital for scans, treatment and appointments with specialists.
I have personally asked four different oncologists if they have heard about IMU, and disappointingly
not one of them have heard of IMU or what they are developing. This I believe is an inditement on
the company. Sure, maybe 99.9 percent of the general market have not or they don't understand
the IP, I get that. It takes a lot of research and understanding to know what's really unfolding here.
But you would think that some oncologists would have heard of what they are developing.
Maybe I was unlucky and found the four that haven't heard of IMU, I will leave that up to you
to judge.
Now back to Paul Hopper. He has been asked many times in the past about listing in the US.
His generally said that its a possibility, but with not much enthusiasm, Up until recently that
is. At the recent presentations in Sydney and Melbourne he seems a lot more positive on
listing in the US. He now says that it would be ideal to list there if we had some real big news to
go with the listing to really make an impacted and hit the ground running over there. He conveys
this with intent in my opinion, others at the presentations can correct me if I'm wrong.
So, for me there has been a big shift in his comments, from maybe one day maybe not, to
IT WOULD BE IDEAL WITH SOME BIG NEWS COMMING TO LIST AT THAT TIME.
Now this is just my opinion but that's a big shift. To me this means they know what's coming,
as Professor Yuman Fong has said recently, he is convinced that this is going to work.
Just remember he never said such strong words before, he was always carful and mentioned
words like we hope to replicate what we have done in the labs and on mice in humans.
In the end yes, the science will do the talking in a big way, I would not be here if I did not
believe that. But the share price is testing us all, I'm sure of that.
Bring on the next set of results, Vaxinia (CF33+hNIS)
CHECKvacc (CF33+hNIS +PD-L1)
These two plus onCARlytics (CF33+CD19) will be huge in my opinion, but the market has
not recognized it yet, but I'm sure in good time the US market will.
Bye the way, I'm not forgetting the b cell treatment, there is plenty value there also.
Wouldn't it be great if IMU could sell the b cell treatments to a big pharama at a
premium price. Then give all shareholders a massive dividend and then go on and
licence the different CF33 platforms to multiple big pharma company's, giving
shareholders some big fat dividends for many years to come.
Thats not that far-fetched if you really think about it.
(20min delay)